Integrated commercialization for a US biotech firm’s first European launch

Inizio helped a client prepare for the European launch of its therapy by serving as a single integrated commercialization partner across strategy, governance, and execution, establishing a scalable and repeatable operating model for use.

What was Inizio’s biotech client looking for?

The client – a US-based biotechnology company with no existing EU footprint – needed support in launching its therapy into the European market following regulatory approval in the US.

Rather than engaging multiple agencies independently, the client wanted a single partner capable of coordinating activities across functions, geographies, and workstreams to ensure the European launch was executed efficiently and consistently.

How did Inizio develop an integrated biotech launch program?

Inizio had been working with the client since 2024, so was uniquely positioned to develop an integrated international launch program. Bringing together broad expertise under a single governance model, the program was designed around three core objectives:

• Enable a scalable international launch by building the capabilities required for successful European commercialization.
• Align cross-functional decision making and board-ready investment planning across the organization.
• Create a single integrated operating model spanning functions and countries.

What did Inizio’s integrated biotech commercialization program include?

A key feature of the engagement was providing one central point of contact for the client – simplifying program governance, Statement of Work management, and coordination across various Inizio teams. The approach included:

• A fully integrated program management office coordinating all workstreams, enabling aligned decision-making and investment planning.
• One commercial interface for the client, reducing complexity and streamlining contracting and program delivery.
• Cross-functional planning and activation across commercial, medical, market access, and brand teams.
• A phased approach to launch readiness that allowed activities to progress in a structured and coordinated manner.

This enabled the client to access the scale and operational agility of Inizio’s deep, broad expertise while avoiding the costs and complexity of working with multiple agencies independently.

What is the value of Inizio’s integrated commercialization approach?

The successful partnership, facilitated through a single governance model, led to:

• Delivery of a fully integrated European commercialization program with knowledge transfer – spanning strategy, program management, Medical Affairs, market access, and commercial readiness.
• Establishment of a scalable operating model to support the client’s expansion into Europe following US approval.
• A long-term partnership and investment plan, with a budget of $51m locked in through 2029, providing strategic clarity to the client and investors.

Partner with Inizio for integrated biotech commercialization

Launching a therapy into a new market requires coordinated strategy, market access, Medical Affairs, commercial readiness, and execution.

Inizio helps biotech and pharma companies simplify commercialization through an integrated launch model that brings specialist capabilities together under one governance structure. Whether you are preparing for your first international launch or expanding an established therapy into new markets, our teams can help you build a scalable commercialization program designed around your business and patient needs.

Get in touch today.